Learn more about personalized care plans in advanced NSCLC with Mark A. Socinski, MD, Maureen F. Zakowski, MD and Victoria Sherry, DNP, CRNP, AOCNP^® as they discuss prognostic markers, current therapies, and adverse event management in this multidisciplinary virtual tumor board.

This case-based presentation developed by Arjun V. Balar, MD, discusses patient and tumor-related factors that can inform personalized care plans as well as novel therapies and adverse event management. Click to learn more and start the activity!

In this multidisciplinary discussion, James B. Bussel, MD & Allison Miller Imahiyerobo, APN explore ITP pathogenesis, current and emerging therapies, and supportive care strategies that help ITP patients achieve their goals of therapy. Register/Sign in to get started!

In this online activity, Srdan Verstovsek, MD, PhD, explores predictive and prognostic markers for personalized care planning in myelofibrosis as well as emerging data in therapeutic strategies and the implications that research advances may have for future practice.

Watch this case-based CME-approved recording with Jamie E. Chaft, MD, as she discusses molecular and clinical factors that can inform first- and second-line treatment strategies for patients with NSCLC.

In this case-based online activity, Miguel-Angel Perales, MD, discusses the graft-versus-leukemia effects of HSCT, emerging data on conditioning and maintenance therapies, and the management of transplant-related complications. Register today!

Patients with TNBC have a poorer prognosis than those who present with HR-positive or HER2-positive disease. This CME/CE-approved discussion on metastatic TNBC with Sara Tolaney, MD, MPH and Sara Hurvitz, MD will evaluate personalized care plans, genetic risk evaluation, and novel therapies.

This online strategy session features a multidisciplinary discussion between Anthony R. Mato, MD, MSCE and Colleen Dorsey, RN, BSN as they discuss risk for TLS, signs and symptoms, as well as prevention and treatment strategies in patients with hematologic malignancies.

How can you improve the treatment outcomes for patients with this rare malignancy? This online activity, led by Morie A. Gertz, MD, MACP and Toni Dubeau, RN, NP, will discuss risk stratification, novel therapeutic approaches, and adverse event management. Start now!

This case-based discussion on metastatic gastric cancer features Jaffer A. Ajani, MD and Allyson J. Ocean, MD as they examine individualized treatment selection, novel therapies, and adverse event management. Register to get started today!